Caffeine (200 mg) — Competitive Intelligence Brief

Caffeine (200 mg) (Caffeine (200 mg)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylxanthine; Central nervous system stimulant. Area: Neurology; General wellness.

marketed Methylxanthine; Central nervous system stimulant Adenosine receptors (A1, A2A, A2B, A3) Neurology; General wellness Small molecule

Target snapshot

Caffeine (200 mg) (Caffeine (200 mg)) — University Hospital, Basel, Switzerland. Caffeine blocks adenosine receptors in the central nervous system, preventing the accumulation of adenosine and reducing drowsiness while increasing alertness and mental focus.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Caffeine (200 mg) TARGET	Caffeine (200 mg)	University Hospital, Basel, Switzerland	marketed	Methylxanthine; Central nervous system stimulant	Adenosine receptors (A1, A2A, A2B, A3)
Caffeine citrate oral solution	Caffeine citrate oral solution	NICHD Global Network for Women's and Children's Health	marketed	Adenosine receptor antagonist; methylxanthine	Adenosine receptors (A1, A2A)
Pentoxifylline sustained-release tablets	Pentoxifylline sustained-release tablets	Beijing Tiantan Hospital	marketed	Methylxanthine derivative; phosphodiesterase inhibitor	Phosphodiesterase
pentoxifylline (PTX)	pentoxifylline (PTX)	Case Western Reserve University	phase 3	Methylxanthine derivative; hemorheological agent	Phosphodiesterase (non-selective); adenosine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methylxanthine; Central nervous system stimulant class)

1. University Hospital, Basel, Switzerland · 1 drug in this class